Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29015218 | 0.84 | MCHR1 (0.40) | BCAT2MCHR1FEN1 | |
| SCHEMBL18291461 | 0.84 | BCAT2 (0.39) | BCAT2MCHR1EP300 | |
| SCHEMBL410479 | 0.78 | CHRNB2 (0.54) | — | |
| SCHEMBL30126846 | 0.74 | EP300 (0.46) | PARP15PARP10PARP2EP300 | |
| SCHEMBL2698965 | 0.74 | EP300 (0.46) | PARP15PARP10PARP2EP300 | |
| SCHEMBL29417253 | 0.74 | ACACB (0.38) | PARP15PARP10PARP2 | |
| SCHEMBL16838831 | 0.74 | ACACB (0.38) | PARP15PARP10PARP2 | |
| SCHEMBL2728360 | 0.73 | MCHR1 (0.50) | MCHR1PARP15PARP10PARP2EP300 | |
| SCHEMBL15968757 | 0.73 | KMO (0.42) | PARP15PARP10PARP2 | |
| SCHEMBL2349832 | 0.72 | BCAT2 (0.47) | BCAT2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116390917-A | MRGX2 antagonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2022152852-A1 | ANTAGONISTS OF MRGX2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022073904-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-7759349-B2 | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1699799-B1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES | SCHERING PLOUGH LTD (CH) | 2007-05-16 | — | — | EP | disclosed |
| EP-1699799-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES | Schering-Plough Ltd. (CH) | 2006-09-13 | — | — | EP | disclosed |
| US-20050182059-A1 | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2005-08-18 | — | — | US | disclosed |
| WO-2005066177-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | SCHERING-PLOUGH LTD. (CH) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182059-A1 | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives | PLPBP, PIR, PPIP5K2 | BCAT2 2343/4885MCHR1 909/4885PARP15 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.